Table 2.
Details of recurrent patients and their failure patterns.
| No. | Primary tumor site | Stage | RT dose (Gy/fr) | Concurrent chemotherapy | Time to failure (Months) | Site of recurrence | Patterns of failure |
|---|---|---|---|---|---|---|---|
| 1 | Nasopharynx | III | 50 Gy/25 + 20 Gy/10 | Nedaplatin | 19 | Local | In field |
| 2 | Nasopharynx | III | 50 Gy/25 + 20 Gy/10 | Paclitaxel liposome | 65 | Regional | In field |
| 3 | Nasopharynx* | III | 44 Gy/20 + 22 Gy/10 + 4 Gy/2 | Nedaplatin | 14 | Local | In field |
| 4 | Nasopharynx | III | 44 Gy/20 + 22 Gy/10 + 4 Gy/2 | Paclitaxel liposome | 49 | Regional | Marginal |
| 5 | Nasopharynx* | III | 50 Gy/25 + 20 Gy/10 | Nedaplatin | 30 | Local-regional | In field |
| 6 | Nasopharynx* | III | 50 Gy/25 + 20 Gy/10 | Nedaplatin | 17 | Local-regional | In field |
| 7 | Nasopharynx | III | 44 Gy/20 + 22 Gy/10 + 4.4 Gy/2 | Nedaplatin | 54 | Regional | Out of field |
| 8 | Nasopharynx* | III | 50 Gy/25 + 20 Gy/10 | Nedaplatin | 8 | Local | In field |
| 9 | Nasopharynx* | III | 44Gy/20 + 22 Gy/10 + 4.4 Gy/2 | Docetaxel | 34 | Local-regional | In field |
| 10 | Nasopharynx* | IVa | 44 Gy/20 + 22 Gy/10 + 6.6 Gy/3 | Nedaplatin | 26 | Local | In field |
| 11 | Nasopharynx | III | 66 Gy/30 + 4 Gy/2 | Docetaxel+oxaliplatin | 27 | Local | In field |
| 12 | Nasopharynx* | III | 50 Gy/25 + 20 Gy/10 | Nedaplatin | 11 | Regional | In field |
| 13 | Nasopharynx* | III | 50 Gy/25 + 20 Gy/10 | Docetaxel | 41 | Regional | In field |
| 14 | Nasopharynx | IVa | 50 Gy/25 + 20 Gy/10 + 4 Gy/2 | Cetuximab+Nedaplatin | 26 | Local | In field |
| 15 | Nasopharynx* | III | 50 Gy/25 + 20 Gy/10 | Nedaplatin | 26 | Regional | In field |
| 16 | Nasopharynx | IVa | 44 Gy/20 + 22 Gy/10 + 4.4 Gy/2 | Docetaxel | 51 | Regional | In field |
| 17 | Nasopharynx | III | 50 Gy/25 + 20 Gy/10 | Oxaliplatin | 41 | Regional | In field |
| 18 | Nasopharynx* | III | 44 Gy/20 + 22 Gy/10 + 4.4 Gy/2 | Nedaplatin | 33 | Local | In field |
| 19 | Nasopharynx* | III | 50 Gy/25 + 20 Gy/10 | Paclitaxel liposome | 14 | Local | In field |
| 20 | Nasopharynx | III | 50 Gy/25 + 20 Gy/10 + 4 Gy/2 | Nedaplatin | 23 | Local | In field |
*
11 NPC-IFRs (in field recurrence) with pre-treatment MRI images available are subsequently used for radiomic analysis